title: Treatment of primary intraocular lymphoma with intravitreal methotrexate.
abstract: OBJECTIVE
  To report the efficacy of intravitreal chemotherapy for primary intraocular lymphoma (PIOL).
  
  
  METHODS
  Retrospective, noncomparative interventional case reports are presented for six patients (ten eyes; mean age, 58.8 years) with pathologically confirmed PIOL who participated in this study and were treated at our hospital with intravitreal injections of methotrexate (MTX) between January 2004 and February 2007. Intravitreal injections of MTX (400 microg MTX/50 microl Opeguard-MA) were administered once or twice weekly for 1 month followed by ten monthly injections. Interleukin-10 (IL-10) and IL-6 were measured in the vitreous before and after injections to determine tumor activity.
  
  
  RESULTS
  All eyes were clinically cleared of malignant cells. One eye lost vision. After intravitreal chemotherapy, the vitreous IL-10 concentration reached barely detectable levels.
  
  
  CONCLUSIONS
  Intravitreal chemotherapy achieves clinical remission and preserves vision in patients with PIOL.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
authors.forename: Reika
authors.initials: R
authors.lastname: Sou
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. nohguro@ophthal.med.osaka-u.ac.jp.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ohguro
authors.affiliation: Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Maeda
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Saishin
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019233:Retreatment; D012189:Retrospective Studies; D016896:Treatment Outcome; D014822:Vitreous Body / Q000378:metabolism
chemical_list: D000964:Antimetabolites, Antineoplastic; C508609:IL10 protein, human; C508600:IL6 protein, human; D015850:Interleukin-6; D016753:Interleukin-10; D008727:Methotrexate